<p>A method for modifying Parkinson's disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to the patient, thereby modifying the disease. The method includes reducing the rate of progression; delaying the need for symptomatic anti-Parkinsonian therapy; reducing the risk of a Parkinson's disease patient requiring symptomatic anti-Parkinsonian therapy; and reducing the functional decline.</p>
申请公布号
WO2009151625(A1)
申请公布日期
2009.12.17
申请号
WO2009US03528
申请日期
2009.06.12
申请人
TEVA PHARMACEUTICAL INDUSTRIES, LTD.;TEVA PHARMACEUTICALS USA, INC.